Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: Report of the French registry and analysis of subgroups of lymphomas

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 682-693

  Caillard, S ^a   Lamy, F X ^b   Quelen, C ^b   Dantal, J ^c   Lebranchu, Y ^d   Lang, P ^e   Velten, M ^a   Moulin, B ^a  

^a Strasbourg Universitary Hospital   (France)

^b Direction Prélèvement Greffe Organes Tissus DPGOT   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Tours Hospital   (France)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

Epidemiology; immunosuppression; incidence; kidney transplantation; posttransplant lymphoproliferative disorders; risk factors

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CYTOMEGALOVIRUS; DEATH; EPSTEIN BARR VIRUS; FEMALE; FRANCE; GRAFT REJECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SEROLOGY; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 84857526313     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03896.x     Document Type: Article

References (36)

1. Starzl TE, Nalesnik MA, Porter KA, et al,. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587. (Pubitemid 14156511)
2. Opelz G, Dohler B,. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003; 4: 222-230.
3. Opelz G, Henderson R,. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516. (Pubitemid 23362168)
4. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K,. Post-transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243. (Pubitemid 41746802)
5. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE,. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065-1068. (Pubitemid 32448820)
6. Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, et al,. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 1985; 152: 876-886. (Pubitemid 16236674)
7. Holmes RD, Sokol RJ,. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456-464. (Pubitemid 35470542)
8. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA,. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56: 88-96. (Pubitemid 23220578)
9. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW,. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293. (Pubitemid 37430713)
10. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B,. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233. (Pubitemid 43804539)
11. Robson R, Cecka JM, Opelz G, Budde M, Sacks S,. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960. (Pubitemid 43923957)
12. Bustami RT, Ojo AO, Wolfe RA, et al,. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93. (Pubitemid 38155493)
13. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C,. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913. (Pubitemid 38745589)
14. van Leeuwen MT, Grulich AE, Webster AC, et al,. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630-637.
15. Faull RJ, Hollett P, McDonald SP,. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005; 80: 193-197. (Pubitemid 41061675)
16. Maisonneuve P, Agodoa L, Gellert R, et al,. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 354: 93-99. (Pubitemid 29313142)
17. Vajdic CM, van Leeuwen MT, Webster AC, et al,. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009; 18: 2297-2303.
18. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE,. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993-998. (Pubitemid 36330232)
19. Olagne J, Caillard S, Gaub MP, Chenard MP, Moulin B,. Post-transplant lymphoproliferative disorders: Determination of donor/recipient origin in a large cohort of kidney recipients. Am J Transplant 2011; 11: 1260-1269.
20. Birkeland SA,. Chronic antigenic stimulation from the graft as a possible oncogenic factor after renal transplant. Scand J Urol Nephrol 1983; 17: 355-359. (Pubitemid 14214483)
21. Caillard S, Pencreach S, Braun L, et al,. Simultaneous development of lymphoma in recipients of renal transplants from a single donor: Donor origin confirmed by human leukocytes antigen staining and microsatellite analysis. Transplantation 2005; 79: 79-84. (Pubitemid 40140004)
22. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA,. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206-209.
23. Alexander DD, Mink PJ, Adami HO, et al,. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer 2007; 120 (Suppl 12): 1-39. (Pubitemid 46732571)
24. Bhagavathi S, Wilson JD,. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008; 132: 1830-1834.
25. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al,. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-918. (Pubitemid 12148553)
26. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL,. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461-472. (Pubitemid 15036441)
27. Walker RC, Marshall WF, Strickler JG, et al,. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
28. McDonald RA, Smith JM, Ho M, et al,. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984-989. (Pubitemid 351537758)
29. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al,. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749-1753. (Pubitemid 351411934)
30. Wu TT, Blackman MA, Sun R,. Prospects of a novel vaccination strategy for human gamma-herpesviruses. Immunol Res 2010; 48: 122-146.
31. Bakker NA, van Imhoff GW, Verschuuren EA, et al,. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80: 595-599. (Pubitemid 41377744)
32. Opelz G, Dohler B,. Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation 2010; 89: 567-572.
33. Kirk AD, Cherikh WS, Ring M, et al,. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619-2625. (Pubitemid 47561615)
34. Dharnidharka VR, Stevens G,. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622-626. (Pubitemid 41413502)
35. Funch DP, Ko HH, Travasso J, et al,. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005; 80: 1174-1180. (Pubitemid 41746793)
36. Birkeland SA, Andersen HK, Hamilton-Dutoit SJ,. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: Use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 67: 1209-1214. (Pubitemid 29239469)